Voleon Capital Management LP Takes $2.11 Million Position in Bristol-Myers Squibb (NYSE:BMY)

Voleon Capital Management LP acquired a new stake in Bristol-Myers Squibb (NYSE:BMY - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 37,313 shares of the biopharmaceutical company's stock, valued at approximately $2,110,000.

Several other hedge funds also recently made changes to their positions in the company. Utah Retirement Systems boosted its stake in shares of Bristol-Myers Squibb by 0.3% during the fourth quarter. Utah Retirement Systems now owns 336,430 shares of the biopharmaceutical company's stock worth $19,028,000 after buying an additional 900 shares during the period. Schonfeld Strategic Advisors LLC increased its holdings in shares of Bristol-Myers Squibb by 45.1% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 664,205 shares of the biopharmaceutical company's stock valued at $37,567,000 after purchasing an additional 206,404 shares during the period. AQR Capital Management LLC grew its position in Bristol-Myers Squibb by 2.7% in the 4th quarter. AQR Capital Management LLC now owns 4,006,797 shares of the biopharmaceutical company's stock valued at $226,624,000 after buying an additional 106,630 shares during the last quarter. Northern Trust Corp increased its stake in Bristol-Myers Squibb by 16.2% in the 4th quarter. Northern Trust Corp now owns 24,658,360 shares of the biopharmaceutical company's stock valued at $1,394,677,000 after buying an additional 3,431,248 shares during the period. Finally, Shorepoint Capital Partners LLC lifted its stake in shares of Bristol-Myers Squibb by 2.2% in the 4th quarter. Shorepoint Capital Partners LLC now owns 58,426 shares of the biopharmaceutical company's stock worth $3,305,000 after acquiring an additional 1,248 shares during the period. Hedge funds and other institutional investors own 76.41% of the company's stock.

Bristol-Myers Squibb Stock Performance

Shares of NYSE BMY traded down $0.52 during trading on Monday, reaching $50.05. The stock had a trading volume of 11,184,423 shares, compared to its average volume of 12,963,314. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25. The stock has a market cap of $101.86 billion, a PE ratio of -11.32, a P/E/G ratio of 2.07 and a beta of 0.41. Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $63.33. The firm's 50 day moving average price is $55.68 and its two-hundred day moving average price is $56.41.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, topping the consensus estimate of $1.50 by $0.30. The firm had revenue of $11.20 billion during the quarter, compared to analysts' expectations of $10.77 billion. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. Bristol-Myers Squibb's quarterly revenue was down 5.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($4.40) EPS. On average, research analysts forecast that Bristol-Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, May 1st. Stockholders of record on Friday, April 4th were issued a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a dividend yield of 4.96%. The ex-dividend date was Friday, April 4th. Bristol-Myers Squibb's dividend payout ratio (DPR) is 92.88%.

Wall Street Analyst Weigh In

A number of research firms have commented on BMY. Citigroup raised their target price on Bristol-Myers Squibb from $60.00 to $65.00 and gave the company a "neutral" rating in a report on Tuesday, January 28th. UBS Group reduced their price target on shares of Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating for the company in a research report on Friday, April 11th. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $55.00 price objective on shares of Bristol-Myers Squibb in a research note on Tuesday, April 22nd. Jefferies Financial Group lowered their target price on Bristol-Myers Squibb from $70.00 to $68.00 and set a "buy" rating on the stock in a report on Wednesday, April 23rd. Finally, Truist Financial lifted their price target on Bristol-Myers Squibb from $62.00 to $65.00 and gave the stock a "buy" rating in a research note on Wednesday, January 8th. Two equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have issued a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat, Bristol-Myers Squibb currently has an average rating of "Hold" and an average target price of $58.00.

Insider Activity at Bristol-Myers Squibb

In related news, EVP Samit Hirawat purchased 1,823 shares of the company's stock in a transaction on Friday, February 14th. The shares were bought at an average cost of $54.84 per share, for a total transaction of $99,973.32. Following the transaction, the executive vice president now owns 63,932 shares of the company's stock, valued at $3,506,030.88. This represents a 2.94 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 0.09% of the company's stock.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.